Katherine Stueland Sells 3,661 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,661 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $76.37, for a total value of $279,590.57. Following the completion of the transaction, the chief executive officer now directly owns 62,897 shares of the company’s stock, valued at approximately $4,803,443.89. This trade represents a 5.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total value of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total value of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $143,456.40.

GeneDx Price Performance

NASDAQ:WGS opened at $71.77 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The firm has a market cap of $1.97 billion, a PE ratio of -23.08 and a beta of 2.04. GeneDx Holdings Corp. has a 12 month low of $1.66 and a 12 month high of $89.11. The company’s 50-day moving average price is $69.70 and its two-hundred day moving average price is $44.98.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. The firm had revenue of $76.90 million during the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business’s revenue was up 44.3% on a year-over-year basis. During the same period last year, the firm posted ($0.82) EPS. On average, equities analysts anticipate that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On GeneDx

A number of large investors have recently modified their holdings of WGS. Acadian Asset Management LLC acquired a new stake in shares of GeneDx in the 2nd quarter valued at $34,000. nVerses Capital LLC acquired a new position in GeneDx during the 2nd quarter valued at about $50,000. CWM LLC bought a new position in shares of GeneDx in the 3rd quarter valued at about $89,000. SG Americas Securities LLC acquired a new position in GeneDx in the third quarter valued at approximately $198,000. Finally, Point72 DIFC Ltd acquired a new position in GeneDx in the third quarter valued at approximately $220,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on WGS. The Goldman Sachs Group lifted their target price on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Craig Hallum lifted their price objective on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company increased their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.